Reversal of Chemoresistance in Ovarian Cancer by Co-delivery of a p-glycoprotein Inhibitor and Paclitaxel in a Liposomal Platform
Molecular Cancer Therapeutics (2016)
Institution: University of Chicago, Cancer
Cell Line: SKOV 3 TR cells (Ovarian cancer cell line)
Research Area: Cancer research
Conclusions: The authors created a nanoparticle formulation against chemotherapy resistant ovarian cancer, loaded with the commonly used cancer drug paclitaxel together with a drug that breaks down the resistance mechanism of cancer cells. Using HoloMonitor, the scientists were able to show that paclitaxel-resistant ovarian cancer cells stopped multiplying when treated with the nanoparticles.